Advitech and PL Thomas (PLT) have concluded a non-exclusive distribution agreement with a yearly commitment for Advitech’s XP-828L ingredient, a patent-pending composition consisting of growth factors, especially TGF- B2, capable to maintain healthy cytokines levels and to support inflammatory process.
Other products of the Advitech portfolio, as well as several new innovations, could be added in the Advitech-PLT agreement upon further discussions, the two companies said.
Luc Clouatre, vice-president of business development, sales and marketing at Advitech, said: “The agreement with PLT is significant as it is an important player in several segments of the American market targeted by Advitech. PL Thomas has strong market visibility and existing business with many of the companies in the food and dietary supplements industry.”